€25.20
Your prediction
Financial data and news for Agios
sharewise wants to provide you with the best news and tools for Agios, so we directly link to the best financial data sources.
Financials
News
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Key Points
- Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better.
- Agios said its rare hematology strategy is gaining momentum, pointing to a “very strong” early launch
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) rose by 11.2% this week, putting the stock into positive territory for the year. The move comes after a well-received first-quarter earnings report
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Agios Pharmaceuticals (NASDAQ: AGIO) was a standout stock in the healthcare sector on Hump Day. Investors eagerly snapped up the company's shares after it unveiled its latest quarterly earnings
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 26.8% in the week as of the time of writing. The move comes after a much larger pharmaceutical company, Novo Nordisk (NYSE: NVO), announced
Here's Why Agios Pharmaceuticals Crashed 23% Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) slumped by 23% as of 11 a.m. today. As is often the case with small-cap healthcare stocks, the move isn't so much dictated by what the company is doing
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting.
That's
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals (NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME